Rein Therapeutics (NASDAQ:RNTX) Stock Rating Lowered by Brookline Capital Management

Rein Therapeutics (NASDAQ:RNTX) was downgraded by research analysts at Brookline Capital Management from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, MarketBeat.com reports.

A number of other brokerages also recently issued reports on RNTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Wednesday, October 8th. Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a research report on Wednesday. Wall Street Zen downgraded shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. Finally, Loop Capital set a $6.00 target price on shares of Rein Therapeutics in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Price Performance

Shares of RNTX stock opened at $1.34 on Wednesday. The company has a market cap of $35.23 million, a price-to-earnings ratio of -0.51 and a beta of 1.31. Rein Therapeutics has a 1 year low of $1.02 and a 1 year high of $3.50. The firm has a fifty day moving average price of $1.32 and a 200-day moving average price of $1.31.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03. Equities research analysts expect that Rein Therapeutics will post -1.56 EPS for the current year.

Insider Transactions at Rein Therapeutics

In related news, major shareholder Voss Capital, Lp acquired 104,183 shares of Rein Therapeutics stock in a transaction dated Friday, November 14th. The shares were purchased at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the completion of the transaction, the insider directly owned 926,441 shares in the company, valued at approximately $1,130,258.02. This represents a 12.67% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have purchased 380,057 shares of company stock worth $508,618. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Rein Therapeutics

Institutional investors have recently bought and sold shares of the stock. Senvest Management LLC purchased a new position in shares of Rein Therapeutics during the second quarter valued at about $323,000. Sigma Planning Corp bought a new position in Rein Therapeutics during the second quarter valued at approximately $387,000. University of Texas Texas AM Investment Management Co. bought a new position in Rein Therapeutics during the second quarter valued at approximately $716,000. Chicago Partners Investment Group LLC purchased a new position in Rein Therapeutics during the 2nd quarter valued at approximately $64,000. Finally, Exencial Wealth Advisors LLC bought a new stake in Rein Therapeutics in the 2nd quarter worth approximately $43,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.